Sun Pharmaceutical Industries Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kirti Wardhaman Ganorkar
- Full Time Employees
- 28,925
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Sun House Mumbai MA India 400063
- IPO Date
- Jan 1, 1994
- Website
- sunpharma.com
- Similar Companies
- Business
- Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company headquartered in Mumbai, India, founded in 1983. It operates across more than 100 countries, manufacturing and marketing a comprehensive portfolio of medicines that includes generic formulations, branded generics, specialty pharmaceuticals, difficult-to-make technology-intensive products, over-the-counter (OTC) healthcare products, anti-retrovirals, active pharmaceutical ingredients (APIs), and intermediates. Sun Pharma's product offerings span numerous therapeutic areas such as psychiatry, cardiology, neurology, diabetology, gastroenterology, oncology, dermatology, ophthalmology, respiratory, and anti-infectives, among others. The company also markets prominent OTC brands like Faringosept, Revital, and Volini. Recent major developments include Sun Pharma's acquisition of Checkpoint Therapeutics, a targeted oncology and immunotherapy company, which adds the FDA-approved immunotherapy drug UNLOXCYT for advanced cutaneous squamous cell carcinoma to its portfolio, strengthening its onco-dermatology segment globally. The company has entered strategic alliances, including a collaboration with AstraZeneca to enhance the availability of sodium zirconium cyclosilicate for hyperkalemia under the brand Gimliand in India. Sun Pharma is also expanding its manufacturing footprint with a significant Rs 3,000 crore investment in a new production facility in Madhya Pradesh, India. Additionally, the company launched the innovative drug Ilumya® in the Indian market and is focused on specialty pipeline growth and global market expansion amidst evolving pharmaceutical landscape dynamics. Sun Pharma continues to invest heavily in research and development, emphasizing specialty medicines, particularly in dermatology, ophthalmology, and oncology, with a focus on both in-licensing clinical candidates and developing differentiated dosage forms. The company's operations are characterized by a strong generic medicines business complemented by a growing specialty pharmaceuticals segment, positioning it as one of the leading specialty generic pharmaceutical companies globally. Its presence and supply chain reach span multiple geographies, with significant markets including the United States, India, emerging markets, and the rest of the world, focusing on providing affordable, high-quality medicines to diverse healthcare settings. Sun Pharmaceutical Industries Limited is recognized as the fourth largest global specialty generic pharmaceutical company.
Company News
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not Candidates for Curative Surgery or Curative Radiation
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment